Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diabetes Therapy
Published in: Diabetes Therapy 5/2024

Open Access 05-04-2024 | Diabetes Therapy | Review

SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review

Authors: Samuel Seidu, Vicki Alabraba, Sarah Davies, Philip Newland-Jones, Kevin Fernando, Stephen C. Bain, Jane Diggle, Marc Evans, June James, Naresh Kanumilli, Nicola Milne, Adie Viljoen, David C. Wheeler, John P. H. Wilding

Published in: Diabetes Therapy | Issue 5/2024

Login to get access

Abstract

A substantial evidence base supports the use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in the treatment of type 2 diabetes mellitus (T2DM). This class of medicines has demonstrated important benefits that extend beyond glucose-lowering efficacy to protective mechanisms capable of slowing or preventing the onset of long-term cardiovascular, renal and metabolic (CVRM) complications, making their use highly applicable for organ protection and the maintenance of long-term health outcomes. SGLT2is have shown cost-effectiveness in T2DM management and economic savings over other glucose-lowering therapies due to reduced incidence of cardiovascular and renal events. National and international guidelines advocate SGLT2i use early in the T2DM management pathway, based upon a plethora of supporting data from large-scale cardiovascular outcome trials, renal outcomes trials and real-world studies. While most people with T2DM would benefit from CVRM protection through SGLT2i use, prescribing hesitancy remains, potentially due to confusion concerning their place in the complex therapeutic paradigm, variation in licensed indications or safety perceptions/misunderstandings associated with historical data that have since been superseded by robust clinical evidence and long-term pharmacovigilance reporting. This latest narrative review developed by the Improving Diabetes Steering Committee (IDSC) outlines the place of SGLT2is within current evidence-informed guidelines, examines their potential as the standard of care for the majority of newly diagnosed people with T2DM and sets into context the perceived risks and proven advantages of SGLT2is in terms of sustained health outcomes. The authors discuss the cost-effectiveness case for SGLT2is and provide user-friendly tools to support healthcare professionals in the correct application of these medicines in T2DM management. The previously published IDSC SGLT2i Prescribing Tool for T2DM Management has undergone updates and reformatting and is now available as a Decision Tool in an interactive pdf format as well as an abbreviated printable A4 poster/wall chart.
Appendix
Available only for authorised users
Literature
1.
Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S, et al. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Ther. 2018;9:1757–73.PubMedPubMedCentralCrossRef
2.
Ali A, Bain S, Hicks D, Newland Jones P, Patel DC, Evans M, et al. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c-translating evidence into practice. Diabetes Ther. 2019;10:1595–622.PubMedPubMedCentralCrossRef
3.
Wheeler DC, James J, Patel D, Viljoen A, Ali A, Evans M, et al. SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes. Diabetes Ther. 2020;11:2757–74.PubMedPubMedCentralCrossRef
4.
Wilding JPH, Evans M, Fernando K, Gorriz JL, Cebrian A, Diggle J, et al. The place and value of sodium-glucose cotransporter 2 inhibitors in the evolving treatment paradigm for type 2 diabetes mellitus: a narrative review. Diabetes Ther. 2022;13:847–72.PubMedPubMedCentralCrossRef
5.
Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43:501–11.PubMedCrossRef
6.
Almigbal TH, Alzarah SA, Aljanoubi FA, Alhafez NA, Aldawsari MR, Alghadeer ZY, et al. Clinical inertia in the management of type 2 diabetes mellitus: a systematic review. Medicina (Kaunas). 2023;59:182.PubMedCrossRef
7.
Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19:185.PubMedPubMedCentralCrossRef
8.
National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline. NG28. 2022.
9.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022, a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925–66.PubMedPubMedCentralCrossRef
10.
IQVIA. Longitudinal prescription data: SGLT2 inhibitor prescribing data for England. 2023.
11.
Thomas MC, Neuen BL, Twigg SM, Cooper ME, Badve SV. SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review. Endocr Connect. 2023;12: e230005.PubMedPubMedCentralCrossRef
12.
Evans M, Morgan AR, Bain SC, Davies S, Dashora U, Sinha S, et al. Defining the role of SGLT2 inhibitors in primary care: time to think differently. Diabetes Ther. 2022;13:889–911.PubMedPubMedCentralCrossRef
13.
14.
15.
Matthews D, Del Prato S, Mohan V, Mathieu C, Vencio S, Chan JCN, et al. Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther. 2020;11:2465–76.PubMedPubMedCentralCrossRef
16.
Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials. J Am Heart Assoc. 2019;8: e012356.PubMedPubMedCentralCrossRef
17.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.PubMedCrossRef
18.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57.PubMedCrossRef
19.
Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation. 2021;144:1284–94.PubMedPubMedCentralCrossRef
20.
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction. Circulation. 2021;143:326–36.PubMedCrossRef
21.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–306.PubMedCrossRef
22.
Heerspink HJL, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28:368–75.PubMedCrossRef
23.
Barraclough JY, Yu J, Figtree GA, Perkovic V, Heerspink HJL, Neuen BL, et al. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2022;24:1072–83.PubMedCrossRef
24.
Gonzalez Perez A, Vizcaya D, Sáez ME, Lind M, Garcia Rodriguez LA. Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK. BMJ Open Diabetes Res Care. 2023;11: e003072.PubMedPubMedCentralCrossRef
25.
Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23:3651.PubMedPubMedCentralCrossRef
26.
Forbes AK, Suckling RJ, Hinton W, Feher MD, Banerjee D, Cole NI, et al. Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: a systematic review and meta-analysis of observational studies. Diabetes Obes Metab. 2023;25:2310–30.PubMedCrossRef
27.
Lo KB, Gul F, Ram P, Kluger AY, Tecson KM, McCullough PA, et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med. 2020;10:1–10.PubMedCrossRef
28.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46.PubMedCrossRef
29.
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425–35.PubMedCrossRef
30.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–9.PubMedCrossRef
31.
The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117–27.CrossRef
32.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO. clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;2022(102):S1-127.
33.
Seidu S, Cos X, Brunton S, Harris SB, Jansson SPO, Mata-Cases M, et al. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Prim Care Diabetes. 2022;16:223–44.PubMedCrossRef
34.
Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6: e009417.PubMedPubMedCentralCrossRef
35.
Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783–94.PubMedCrossRef
36.
Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788–801.CrossRef
37.
38.
Scheen AJ. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review. Expert Rev Endocrinol Metab. 2023;18:271–82.PubMedCrossRef
39.
Chipayo-Gonzales D, Shabbir A, Vergara-Uzcategui C, Nombela-Franco L, Jimenez-Quevedo P, Gonzalo N, et al. Treatment with SGLT2 inhibitors in patients with diabetes mellitus and extensive coronary artery disease: mortality and cardiovascular outcomes. Diabetes Ther. 2023;14:1853–65.PubMedPubMedCentralCrossRef
40.
Strain WD, Cos X, Hirst M, Vencio S, Mohan V, Vokó Z, et al. Time to do more: addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2014;105:302–12.PubMedCrossRef
41.
McEwan P, Foos V, Martin B, Chen J, Evans M. Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence. Diabetes Obes Metab. 2023;25:1830–8.PubMedCrossRef
42.
Morton JI, Marquina C, Shaw JE, Liew D, Polkinghorne KR, Ademi Z, et al. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia. 2023;66:642–56.PubMedCrossRef
43.
Yoshida Y, Cheng X, Shao H, Fonseca VA, Shi L. A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes. Curr Diab Rep. 2020;20:12.PubMedCrossRef
44.
Chin KL, Ofori-Asenso R, Si S, Hird TR, Magliano DJ, Zoungas S, et al. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. Sci Rep. 2019;9:3256.PubMedPubMedCentralCrossRef
45.
Hodgson S, Morgan-Harrisskitt J, Hounkpatin H, Stuart B, Dambha-Miller H. Primary care service utilisation and outcomes in type 2 diabetes: a longitudinal cohort analysis. BMJ Open. 2022;12: e054654.PubMedPubMedCentralCrossRef
46.
Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019;17:145.PubMedPubMedCentralCrossRef
47.
Zghebi SS, Steinke DT, Rutter MK, Ashcroft DM. Eleven-year multimorbidity burden among 637 255 people with and without type 2 diabetes: a population-based study using primary care and linked hospitalisation data. BMJ Open. 2020;10: e033866.PubMedCrossRef
48.
Ceriello A, Lucisano G, Prattichizzo F, La Grotta R, Frigé C, De Cosmo S, et al. The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes. Lancet Region Health Eur. 2023;31: 100666.CrossRef
49.
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249–59.PubMedPubMedCentralCrossRef
50.
Khunti K, Kosiborod M, Kim DJ, Kohsaka S, Lam CSP, Goh S-Y, et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovasc Diabetol. 2021;20:159.PubMedPubMedCentralCrossRef
51.
Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8:27–35.PubMedCrossRef
52.
Gorgojo-Martinez JJ, Ferreira-Ocampo PJ, Galdón Sanz-Pastor A, Cárdenas-Salas J, Antón-Bravo T, Brito-Sanfiel M, et al. Effectiveness and tolerability of the intensification of canagliflozin dose from 100 mg to 300 mg daily in patients with type 2 diabetes in real life: the INTENSIFY study. J Clin Med. 2023;12:4248.PubMedPubMedCentralCrossRef
53.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.PubMedCrossRef
54.
Yu J, Arnott C, Neuen BL, Heersprink HL, Mahaffey KW, Cannon CP, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Fail. 2021;8:1482–93.PubMedPubMedCentralCrossRef
55.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–34.PubMedCrossRef
56.
Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606–17.PubMedCrossRef
57.
Blonde L, Stenlöf K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016;128:371–80.PubMedCrossRef
58.
Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–31.PubMedCrossRef
59.
Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13:119–26.PubMedCrossRef
60.
Pratama K. Weight loss effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with obesity without diabetes: a systematic review. Acta Endocrinol (Bucharest). 2022;18:216–24.CrossRef
61.
Weingold R, Zinman B, Mattheus M, Ofstad AP, Steubl D, Wanner C, et al. Shifts in KDIGO CKD risk groups with empagliflozin: kidney-protection from SGLT2 inhibition across the spectrum of risk. J Diabetes Complic. 2023;37: 108628.CrossRef
62.
63.
64.
65.
66.
67.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726.PubMedCrossRef
68.
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.PubMedCrossRef
69.
Evans M, Morgan AR, Davies S, Beba H, Strain WD. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing. 2022;51:afac201.PubMedPubMedCentralCrossRef
70.
71.
TODAY Study Group, Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, et al. Long-term complications in youth-onset type 2 diabetes. N Engl J Med. 2021;385:416–26.PubMedCentralCrossRef
72.
73.
74.
75.
Butler J, Usman MS, Filippatos G, Ferreira JP, Böhm M, Brueckmann M, et al. Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction. JAMA Cardiol. 2023;8:640.PubMedPubMedCentralCrossRef
76.
Shen L, Kristensen SL, Bengtsson O, Böhm M, de Boer RA, Docherty KF, et al. Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF. JACC Heart Fail. 2021;9:254–64.PubMedCrossRef
77.
Peasah SK, Huang Y, Palli SR, Swart EC, Donato BM, Pimple P, et al. Real-world impact of empagliflozin on total cost of care in adults with type 2 diabetes: Results from an outcomes-based agreement. J Manag Care Spec Pharm. 2023;29:152–60.PubMed
78.
Choi JG, Winn AN, Skandari MR, Franco MI, Staab EM, Alexander J, et al. First-line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. Ann Intern Med. 2022;175:1392–400.PubMedPubMedCentralCrossRef
79.
National Institute for Health and Care Excellence. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes. Technology appraisal guidance [TA390] [Internet]. 2016 [cited 2024 Jan 17]. https://​www.​nice.​org.​uk/​guidance/​ta390. Accessed 14 Mar 2024
80.
Kanumilli N, Brunton S, Cos X, Deed G, Kushner P, Lin P, et al. Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management. J Diabetes Complic. 2021;35: 107813.CrossRef
81.
82.
83.
Brown P. Need to know guide: SGLT2 inhibitor indications, doses and licences (updated 2023). Diabetes Prim Care. 2023;25:9–10.
84.
Diggle J. Ketones and diabetes. Diabetes Prim Care. 2020;22:49–50.
85.
86.
Umapathysivam MM, Gunton J, Stranks SN, Jesudason D. Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction. Diabetes Care. 2023;47:1–4.
87.
Brown P. How to use SGLT2 inhibitors safely and effectively. Diabetes Prim Care. 2023;25:113–5.
88.
Vadi S, Lad V, Kapoor D. Perioperative implication of sodium-glucose cotransporter-2 inhibitor in a patient following major surgery. Indian J Crit Care Med. 2021;25:958–9.PubMedPubMedCentralCrossRef
89.
90.
Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium–glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections. Ann Intern Med. 2019;171:248–56.PubMedPubMedCentralCrossRef
91.
92.
Kang A, Smyth B, Neuen BL, Heerspink HJL, Di Tanna GL, Zhang H, et al. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: a pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes Obes Metab. 2023;25:2151–62.PubMedCrossRef
93.
Dass AS, Immaculate G, Bhattacharyya A. Fournier’s gangrene and sodium-glucose co-transporter 2 (SGLT2) inhibitors: our experience. Indian J Endocrinol Metab. 2019;23:165–6.PubMedPubMedCentralCrossRef
94.
Yang JY, Wang T, Pate V, Buse JB, Stürmer T. Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene. BMJ Open Diabetes Res Care. 2020;8: e000985.PubMedPubMedCentralCrossRef
95.
Chowdhury T, Gousy N, Bellamkonda A, Dutta J, Zaman CF, Zakia UB, et al. Fournier’s Gangrene: a coexistence or consanguinity of SGLT-2 inhibitor therapy. Cureus. 2022;14: e27773.PubMedPubMedCentral
96.
97.
Schaper NC, Netten JJ, Apelqvist J, Bus SA, Hinchliffe RJ, Lipsky BA. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36: e3266.PubMedCrossRef
98.
See RM, Teo YN, Teo YH, Syn NL, Yip ASY, Leong S, et al. Effects of sodium-glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials. Pharmacology. 2022;107:123–30.PubMedCrossRef
99.
Scheen AJ. Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: a meta-analysis of observational studies. Diabetes Epidemiol Manag. 2022;6: 100054.CrossRef
100.
Baker N. Diabetic foot care: a guide for non-specialists. J Diabetes Nurs. 2020;24:JDN144.
101.
Strain WD, Down S, Brown P, Puttanna A, Sinclair A. Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes. Diabetes Ther. 2021;12:1227–47.PubMedPubMedCentralCrossRef
102.
Rong X, Li X, Gou Q, Liu K, Chen X. Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials. Diab Vasc Dis Res. 2020;17:147916412095362.CrossRef
103.
Jackson AM, Dewan P, Anand IS, Bělohlávek J, Bengtsson O, de Boer RA, et al. Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation. 2020;142:1040–54.PubMedPubMedCentralCrossRef
104.
van Ruiten CC, Hesp AC, van Raalte DH. Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: update on recent mechanistic insights related to kidney physiology. Eur J Intern Med. 2022;100:13–20.PubMedCrossRef
105.
Lam D, Shaikh A. Real-life prescribing of SGLT2 inhibitors: how to handle the other medications, including glucose-lowering drugs and diuretics. Kidney360. 2021;2:742–6.PubMedPubMedCentralCrossRef
106.
107.
Yavin Y, Mansfield TA, Ptaszynska A, Johnsson K, Parikh S, Johnsson E. Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Ther. 2016;7:125–37.PubMedPubMedCentralCrossRef
108.
Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;145:1460–70.PubMedCrossRef
109.
110.
Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021;42:4891–901.PubMedCrossRef
111.
Zannad F, Rossignol P. Mineralocorticoid receptor antagonists and SGLT2 inhibitor therapy: the best of both worlds in HFrEF. JACC Heart Fail. 2021;9:265–7.PubMedCrossRef
112.
Yang S, Zhao L, Mi Y, He W. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. Diabetes Obes Metab. 2022;24:2159–68.PubMedCrossRef
113.
Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021;20:154.PubMedPubMedCentralCrossRef
114.
National Institute for Health and Care Excellence. Finerenone for treating chronic kidney disease in type 2 diabetes. Technology appraisal guidance. TA877 [Internet]. 2023 [cited 2023 Dec 19]. www.​nice.​org.​uk/​guidance/​ta877. Accessed 14 Mar 2024
115.
Ferreira JP, Inzucchi SE, Mattheus M, Meinicke T, Steubl D, Wanner C, et al. Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2022;24:135–41.PubMedCrossRef
116.
Li J, Badve SV, Zhou Z, Rodgers A, Day R, Oh R, et al. The effects of canagliflozin on gout in type 2 diabetes: A post-hoc analysis of the CANVAS Program. Lancet Rheumatol. 2019;1:e220–8.PubMedCrossRef
117.
Lund LC, Højlund M, Henriksen DP, Hallas J, Kristensen KB. Sodium-glucose cotransporter-2 inhibitors and the risk of gout: a Danish population-based cohort study and symmetry analysis. Pharmacoepidemiol Drug Saf. 2021;30:1391–5.PubMedCrossRef
118.
Zhou J, Liu X, Chou OH-I, Li L, Lee S, Wong WT, et al. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes. Rheumatology (Oxford). 2023;62:1501–10.PubMedCrossRef
119.
Fralick M, Chen SK, Patorno E, Kim SC. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med. 2020;172:186–94.PubMedPubMedCentralCrossRef
120.
Wei J, Choi HK, Dalbeth N, Li X, Li C, Zeng C, et al. Gout flares and mortality after sodium-glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes. JAMA Netw Open. 2023;6: e2330885.PubMedPubMedCentralCrossRef
121.
Down S. How to advise on sick day rules. Diabetes Prim Care. 2020;22:47–8.
122.
123.
Dashora U, Gregory R, Winocour P, Dhatariya K, Rowles S, Macklin A, et al. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021). Clin Med (Lond). 2021;21:204–10.PubMedCrossRef
124.
125.
126.
127.
Pellicori P, Fitchett D, Kosiborod MN, Ofstad AP, Seman L, Zinman B, et al. Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. Eur J Heart Fail. 2021;23:1085–93.PubMedCrossRef
128.
Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, et al. SGLT2-inhibitors are effective and safe in the elderly: the SOLD study. Pharmacol Res. 2022;183: 106396.PubMedCrossRef
129.
Butt JH, Jhund PS, Belohlávek J, de Boer RA, Chiang C-E, Desai AS, et al. Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation. 2022;146:1210–24.PubMedPubMedCentralCrossRef
130.
Goldman A, Fishman B, Twig G, Raschi E, Cukierman-Yaffe T, Moshkovits Y, et al. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study. Cardiovasc Diabetol. 2023;22:16.PubMedPubMedCentralCrossRef
131.
132.
133.
134.
135.
136.
Metadata
Title
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
Authors
Samuel Seidu
Vicki Alabraba
Sarah Davies
Philip Newland-Jones
Kevin Fernando
Stephen C. Bain
Jane Diggle
Marc Evans
June James
Naresh Kanumilli
Nicola Milne
Adie Viljoen
David C. Wheeler
John P. H. Wilding
Publication date
05-04-2024
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 5/2024
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-024-01550-5

Other articles of this Issue 5/2024

Diabetes Therapy 5/2024 Go to the issue

Original Research

Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups

Review

Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

Study Protocol

Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study)

Original Research

An Obesity-Centric Approach with and Without Anti-Obesity Medications Compared to the Usual-Care Approach to Management of Patients with Obesity and Type 2 Diabetes in an Employer Setting: A Pragmatic Randomized Controlled Trial (EMPOWER-T2D)

Original Research

Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity

Summary of Research

Summary of Research: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin Versus Placebo and the DPP-4 Inhibitor Linagliptin Versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits